TNGX
Tango Therapeutics, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 25 to Apr 1 ▼ 2 days of insider sells: $813.8K by 1 insider, avg $20.87
- Jun 1 ▼ 1 insider sell $617.6K at $22.87
- Jun 10 Offering: Tango Therapeutics Announces Pricing of $600 Million Upsiz…
- Jul 1 ▼ 1 insider sell $798.9K at $29.59
- Aug 3 ▼ 1 insider sell $735.5K at $27.24
- Sep 1 ▼ 1 insider sell $603.9K at $22.37
- Sep 22 ▼ 1 insider sell $198.6K at $24.22
- Oct 1 ▼ 1 insider sell $660.8K at $24.47
- Oct 16 William Blair initiates
- Oct 23 ▲ Tango Therapeutics reported highly promising Phase 1/2 data for vopi…
- Nov 2 ▼ 2 insiders sell $269.8K at $22.42
- Nov 11 ▼ 1 insider sell $125.0K at $25.00
Signal stack
Where each data set points today.
- InsidersBEARISH
3 insiders sold $7.4M.
- InstitutionsBULLISH
Q3 2026: 34 added (0 new), 19 trimmed or exited.
- AnalystsBULLISH
17 of 19 rate it Buy or better. Median target $46.00 (+90%).
- EstimatesFALLING
Current-quarter EPS estimate −$0.330 → −$0.351 over 90 days. 1 up, 2 down in 30 days.
- Short sellersSTEADY
Short interest +7.7% to 48.24M shares. 9.7 days to cover, ≈28.6% of shares.
- TrendUPTREND
3% above its 50-day average.
- SocialQUIET
No Reddit mentions this week. Last mention Oct 23.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| AMERICAN CENTURY COMPANIES INC | ADD | $32.0M |
| Fisher Asset Management, LLC | ADD | $26.7M |
| Connor, Clark & Lunn Investment Management Ltd. | ADD | $20.9M |
| Jefferies Financial Group Inc. | TRIM | $15.7M |
| UBS Group AG | ADD | $15.0M |
| Assenagon Asset Management S.A. | ADD | $14.9M |
| Candriam S.C.A. | TRIM | $12.0M |
| CONGRESS ASSET MANAGEMENT CO | ADD | $11.9M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
19 analystsPrice is inside the target range. Median implies +90%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 10, 2026 | JP Morgan MAINTAIN | Overweight |
| Nov 10, 2026 | Wedbush MAINTAIN | Outperform |
| Nov 10, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
| Oct 29, 2026 | HC Wainwright & Co. REITERATE | Buy |
| Oct 16, 2026 | William Blair INITIATE | Outperform |
| Aug 18, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Crystal Adam President, R&D Nov 11, 2026 | EXERCISE | $14.6K |
Crystal Adam President, R&D Nov 11, 2026 | SELL | $125.0K |
Crystal Adam President, R&D Nov 2, 2026 | SELL | $25.3K |
Crystal Adam President, R&D Nov 2, 2026 | SELL | $86.8K |
Crystal Adam President, R&D Nov 2, 2026 | EXERCISE | $14.6K |
Newcomb Jessica Principal Accounting Officer Nov 2, 2026 | SELL | $33.6K |
Newcomb Jessica Principal Accounting Officer Nov 2, 2026 | SELL | $124.1K |
Crystal Adam President, R&D Oct 1, 2026 | SELL | $645.6K |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.35 | -$0.42–-$0.30 | +0.1% | $0.00 |
| Next Q | -$0.43 | -$0.50–-$0.33 | -13.9% | $1.1M |
| Current FY | -$1.46 | -$1.63–-$1.14 | -4.3% | $0.00 |
| Next FY | -$1.80 | -$2.36–-$1.24 | -6.7% | $2.6M |
Short side
FINRA· Oct 30, 2026SecBot reports
25 filings · 2 press releases · 6 bullish · 4 bearish · 2 mixed · 13 neutral- BEARISH SC 13G/ANov 16, 2026
TCG Crossover GP II, LLC and related entities filed an amended Schedule 13G reporting a 4.6% passive stake in Tango Therapeutics as of September 30, 2026, down from a prior 5%+ position. The filing indicates the group's stake fell below the 5% threshold, which may signal reduced conviction or…
🔒 Fresh report (last 24h), subscribers only
- BEARISH SC 13G/ANov 16, 2026
Farallon Capital Management filed an amended Schedule 13G reporting a 4.9% passive stake in Tango Therapeutics as of September 30, 2026, down from a prior 5%+ position. The filing indicates Farallon's stake fell below the 5% threshold, which may signal reduced conviction or portfolio rebalancing.
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL PRESS-RELEASENov 9, 2026
Tango Therapeutics reported Q3 2026 net loss of $68.4M ($0.39/share) vs net income of $15.9M…
The vopimetostat data and regulatory engagement plans are the primary value drivers. Monitor FDA feedback on accelerated approval path and Phase 3 initiation in 1H 2027. The cash runway appears…
- NEUTRAL SC 13G/ANov 6, 2026
FMR LLC (Fidelity) filed an amended Schedule 13G reporting beneficial ownership of 25,286,624…
Monitor for any subsequent conversion to a 13D filing, which would signal a shift from passive to activist intent. The increase in FMR's stake is consistent with its role as a top institutional…
All TNGX filing & press-release reports (27)
- SC 13G/A reportNov 16, 2026
- SC 13G/A reportNov 16, 2026
- PRESS-RELEASE reportNov 9, 2026
- SC 13G/A reportNov 6, 2026
- CLUSTER reportNov 4, 2026
- INST-CLUSTER reportNov 2, 2026
- 144 reportNov 2, 2026
- 8-K reportOct 23, 2026
- 8-K reportAug 11, 2026
- 8-K reportAug 11, 2026
- PRESS-RELEASE reportAug 11, 2026
- INST-CLUSTER reportAug 9, 2026
- 8-K reportAug 6, 2026
- 144 reportJun 11, 2026
- INST-CLUSTER reportJun 11, 2026
- INST-CLUSTER reportJun 11, 2026
- 424B5 reportJun 10, 2026
- 144 reportJun 10, 2026
- PRESS-RELEASE reportJun 9, 2026
- 424B5 reportJun 8, 2026
- 8-K reportJun 8, 2026
- 8-K reportMay 8, 2026
- 3 reportApr 24, 2026
- DEFA14A reportApr 17, 2026
- 8-K reportApr 15, 2026
- 8-K reportMar 5, 2026
- PRESS-RELEASE reportMar 5, 2026